Calidi Biotherapeutics, Inc.
CLDI
Positions held
Your positionsCLDI isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $3.82M | Enterprise value | $568,301 | Trailing P/E | — | Forward P/E | -1.16 |
| PEG | — | Price / book | 0.69 | Beta | 1.33 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -6.7% | ROA | -134.8% | Debt / equity | 0.62 |
| Current ratio | 1.68 | Free cash flow | -$10.02M | Analyst recommendation | none | Mean target | — |
| 52w high | $27.84 | 52w low | $0.99 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$4.2M | -$4.1M | -$4.1M | -$5.1M | -$5.7M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$4.2M | -$4.2M | -$4.5M | -$5.0M | -$5.7M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | -51395.6% | — |
| Net income | -$19.9M | -$22.1M | -$29.2M | -$25.4M | — |
| Gross margin | — | — | — | 68.9% | — |
| Gross profit | — | — | $0.0M | $0.0M | $0.4M |
| Operating income | -$20.2M | -$21.6M | -$26.1M | -$23.1M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-25 · Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders’ Equity Deficiency
2026-09-17 · Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering
2026-09-08 · Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
2026-08-13 · Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
2026-07-21 · Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers
2026-07-20 · Calidi Biotherapeutics to Effect 1-for-16 Reverse Stock Split
2026-07-20 · Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026
Price (daily)
Full chart · RSI · MACD · patterns